Literature DB >> 17350606

Serum level of ornithine carbamoyltransferase is influenced by the state of Kupffer cells.

Hiroshi Murayama1, Masaki Ikemoto, Yoshihiro Fukuda, Shoji Tsunekawa, Atsuo Nagata.   

Abstract

BACKGROUND: The ratio of ornithine carbamoyltransferase (OCT) to alanine aminotransferase (ALT) or glutamate dehydrogenase (GDH) in serum has been suggested as an indicator for the diagnosis of hepatocellular carcinoma and alcoholic liver disease, respectively. However, the mechanisms responsible for the increase in these ratios are still unclear.
METHODS: Wistar rats were pretreated with lipopolysaccharide (LPS) or gadolinium chloride (GD) before being administered with thioacetamide (TAA, 200 mg/kg, ip). Serum OCT and ALT levels were compared with control values. Half-lives of the enzymes in circulation were evaluated after the intravenous injection of the purified enzymes into rats with or without the pretreatment.
RESULTS: The serum level of OCT at 24 h after the administration of TAA was significantly lower in the LPS-treated group, and not influenced by pretreatment with GD. The half-life of OCT was prolonged from 1.06+/-0.14 to 2.07+/-0.29 h (p<0.05) by the pretreatment with GD, but not influenced by the administration of LPS. No change was observed in the clearance of GDH or ALT among the pretreatments.
CONCLUSIONS: Leakage into and clearance from the circulation of OCT are influenced by whether Kupffer cells are activated or not. OCT alone or in combination with other markers may be a useful indicator for Kupffer cell activation as well as mitochondrial damage in hepatic cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350606     DOI: 10.1016/j.cca.2007.02.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial.

Authors:  B A Howell; S Q Siler; L K M Shoda; Y Yang; J L Woodhead; P B Watkins
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-05

2.  Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials.

Authors:  D M Longo; G T Generaux; B A Howell; S Q Siler; D J Antoine; D Button; A Caggiano; A Eisen; J Iaci; R Stanulis; T Parry; M Mosedale; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2017-05-27       Impact factor: 6.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.